dermadiagnostics is committed to reducing the incidence of cervical cancer by increasing testing compliance through a non-invasive diagnostic patch. Our patient-centric products deliver accurate, same-day results while reducing diagnostic costs for healthcare providers.
Currently, there is no immediate diagnosis or combined diagnosis-treatment option for gynecologic malignancies such as cervical cancer. This leaves patients vulnerable to greater health risks, including infertility, and the potential of other aggressive types of gynecologic cancers. On a yearly basis there are 7.2 million new cases of cancer of the female reproductive system, of which up to 266,000 result in deaths.
We envision a microneedle mediated diagnostic patch that detects early onset of cervical cancer, replacing invasive procedures such as the Pap smear and cytology. The digitized medical device is able to detect novel targets within 30 to 45 minutes, equivalent to a clinical visit and thereby providing benefits to health professionals for better management of guidelines and improved patient outcomes. The physical, psychological and social consequences of sexual and reproductive health compromise rigorously the quality of life of those ill and at risk. We envision a world in which curable and treatable maladies can be detected before causing irreparable damage.
Meet the dermadiagnostics team!
diapatch™ screens for—
Novel HPV strains
CIN II biomarkers
CIN III biomarkers
Seamless and effortless integration into busy, modern lifestyles, allowing for streamlined, higher quality patient care
non-invasive and accurate diagnosis
Faster, more accurate diagnosis
Non-invasive approach for easier workflow and patient care
Same-day results for appropriate patient triaging for follow-up procedures and treatment
222 W Merchandise Mart Plaza, No. 1230
Chicago, IL 60654
1400 East Angela Blvd.
South Bend, IN 46617
Our Phone No.